الصفحة الرئيسية>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>SS28

SS28

رقم الكتالوجGC37678

SS28 ، التناظرية SRT501 مع التوافر البيولوجي عن طريق الفم ، يمنع بلمرة التوبولين للتسبب في توقف دورة الخلية في مرحلة G2 / Mينتج عن SS28 موت الخلايا المبرمج بدلاً من نخر توبولين

Products are for research use only. Not for human use. We do not sell to patients.

SS28 التركيب الكيميائي

Cas No.: 141172-08-9

الحجم السعر المخزون الكميّة
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SS28, a SRT501 analog with oral bioavailability, inhibits tubulin polymerization to cause cell cycle arrest at G2/M phase. SS28 results in apoptosis rather than necrosis tubulin[1]. Tubulin[1].

SS28 (0-20 μM) induces cytotoxicity in different cancer cell lines[1].SS28 treatment (5 μM for A549 and 2 μM for CEM) results in cell cycle arrest at G2/M phase leading to apoptosis upon further incubation[1]. Cell Proliferation Assay[1] Cell Line: CEM, Reh, Nalm6, SUDHL8, Molt4, A549, HeLa 293T cells.

SS28 (15 mg/kg. b.wt.) treatment results in inhibition of tumor cell proliferation[1]. Animal Model: BALB/c mice using EAC cells[1].

[1]. Thomas E, et al. A Novel Resveratrol Based Tubulin Inhibitor Induces Mitotic Arrest and Activates Apoptosis in Cancer Cells. Sci Rep. 2016 Oct 17;6:34653.

مراجعات

Review for SS28

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SS28

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.